Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.
The International Society on Thrombosis and Haemostasis (ISTH), in partnership with John Wiley and Sons, Inc., announces the launch of the Society's new open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), with its inaugural issue to publish in conjunction with the meeting of the ISTH 2017 Congress in Berlin, Germany, July 8-13.
Qosina is pleased to announce that we have received ISO 13485 Certification, a globally recognized standard that specifies the requirements for a quality management system that can be used by organizations providing medical devices, components and delivery of related services.
Richard Wolf GmbH is presenting its new system solutions for minimally invasive human medicine at the International Trade Fair for Medical Technology – MEDICA 2016, November 14-17, 2016 – at the newly designed exhibition booth under the motto “feel the spirit of excellence”.
Boston Scientific Corporation today announced the launch of the Resolution 360 Clip, a novel technology designed to improve hemostatic clipping by providing physicians controlled rotation designed for more accurate clip placement.
As demand for the widely used blood thinning drug heparin continues to grow, experts worry of possible shortages of the essential medication.
Siemens Healthineers has more than 30 years of central lab hemostasis leadership. Building on to its portfolio, the company announced today FDA 510(k) clearance for a hand-held portable coagulation analyzer.
Roughly one-third of all births in Europe and North America now occur via cesarean section (CS). Following any birth, women are at an increased risk for a venous thromboembolism (VTE), but it's believed that CS leaves women more vulnerable to VTE, blood clots, than vaginal delivery (VD).
Qosina is pleased to announce the addition of eight new barbed check valves to complement their extensive line of stock components. Available in three different configurations, these barbed valves have a low, 0.087 psi cracking pressure.
A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.
When in dysfunction, the vascular endothelium -- the tissue that lines the blood vessels throughout our body's entire circulatory system -- plays a big role in the development of many human diseases, including diabetes, stroke, heart disease, viral infections and cancer.
Today, Siemens Healthineers Laboratory Diagnostics business launched the Sysmex CS-2500 System—a mid-volume, fully-automated coagulation analyzer with smartly-designed PSI technology—in major markets including the U.S. Together with Lab Alliance of Central New York, the first U.S. customer to install the high-volume Sysmex CS-5100 System, the company celebrated the availability of its new Sysmex CS Hemostasis System portfolio in the U.S.
LGC Maine Standards is pleased to announce our VALIDATE D-Dimer calibration verification / linearity test kit has received US FDA 510(k) clearance for use on Instrument Laboratory ACL TOP hemostasis test systems.
Increasing oxygen delivery to muscles can help athletes perform better and give them the edge needed to win elite competitions. One of the best ways to increase oxygen supply is through blood manipulation, undergoing a blood transfusion that provides extra red blood cells and boosts oxygen levels.
Essential Medical, Inc., a privately held medical device company addressing the rapidly growing large bore vascular closure market, announced today that it has received CE Mark approval for MANTA, the company's Large Bore Vascular Closure Device.
More than 20 percent of all blood clots in veins occur in cancer patients. These clots, also known as venous thromboembolism (VTE), pose serious threats for cancer patients.
Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.
Mary Cushman, M.D., M.Sc., a professor of medicine and director of the Thrombosis and Hemostasis Program at the University of Vermont, provides commentary on the causes of life-threatening blood clots in elite athletes.
For many people, coronary artery disease, or CAD—the buildup of plaque in the heart's arteries—is an unfortunate part of aging. By studying the genetic makeup of those who manage to maintain clear arteries into old age, researchers have identified a possible genetic basis for the disease, as well as potential new opportunities to prevent it.
A new study finds significant differences between the blood clot structure in adults and newborns, helping researchers better understand the challenges in addressing post-operative bleeding in neonatal patients.
Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.